Navigation Links
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
Date:12/3/2008

s for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA immunotherapeutics for cancer, in which the expressed protein is an immune system stimulant; DNA vaccines for infectious diseases, in which the expressed protein is an immunogen; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and serve significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the EIP agreement, Allovectin-7(R), and the AIMM trial. Risks and uncertainties include: whether EIP will obtain the necessary regulatory approvals for the Turkish territory; whether EIP will successfully sell and market Allovectin-7(R) in Turkey and the Turkish Republic of Northern Cyprus; whether Vical will achieve any milestones and whether EIP will pay Vical any upfront or milestone payments under the agreement; whether Vical or others will continue development of Allovectin-7(R); whether Vical will be able to recruit patients into the AIMM trial as planned, if at all; whether Vical will receive all of the clinical trial funding from AnGes under the collaborative agreement; whether Allovectin-7(R) or any other product candidates will be shown to be safe and e
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
3. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
4. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
5. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
6. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
8. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
9. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
10. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Intarcia Therapeutics, Inc. today announced successful top-line results ... for ITCA 650 (exenatide, delivered continuously once or twice ... trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical ... 650 in patients with type 2 diabetes against placebo. ... to placebo for both 40 mcg and 60 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a ... used to develop and produce enzymes and other ... industrial enzymes industries, today announced the receipt of ... commercial scale production of Abengoa,s proprietary cellulase enzymes, ... Abengoa,s license agreement with Dyadic. ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... the worldwide leader in handheld x-ray technologies, has been ... Edison Best New Product Awards™. The winners were announced ... ballroom in New York City.  The NOMAD® Handheld X-ray ... Medical Handheld or Miniaturized Devices Segment. ...
... PRA International, a leading Clinical Research Organization, announces that ... will speak at the World Drug Safety Congress being held ... host an exhibit at booth #2. Dr. ... first breakout stream, "Operational Safety," on 13 April at 1:50 ...
Cached Medicine Technology:NOMAD by Aribex Receives Edison Best New Product Award 2PRA International Experts to Speak at Drug Safety Conference 2
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... of developing celiac disease isn,t reduced by breast-feeding. Nor will ... gluten to an infant,s diet help prevent celiac disease. ... studies in the Oct. 2 New England Journal of ... that a child could avoid celiac disease if mothers breast-feed ...
(Date:10/1/2014)... researchers from the University of Adelaide have developed a ... of a good outcome from treatment - from their ... on a range of factors, including clinical symptoms, cognitive ... in the patient,s blood. , Speaking in the lead ... University,s Head of Psychiatry , Professor Bernhard ...
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog ... couples. , Senior citizens can purchase a joint ... loved ones. A joint policy is cheaper, but will ... , Life insurance can be used to cover ... be purchased online, as the application process is simple ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
Breaking Medicine News(10 mins):Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... , , TAMPA, Fla. ... Solutions, today announced the appointment of Michael Unhjem as a member of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090709/FL43703LOGO ) , ... of Blue Cross Blue Shield (BCBS) of North Dakota, was unanimously elected ...
... SEATTLE, July 20 Group Health Cooperative medical centers received ... the Puget Sound Health Alliance Community Checkup . Group ... nine medical groups in the Puget Sound region that were rated on ... regional average" scores. , , "We support ...
... , MINNEAPOLIS, July 20 ... into a business relationship with Cardiocom(R) to provide advanced home ... Experts in Telehealth(SM), is a world class developer, manufacturer and ... , Cardiocom,s telehealth system provides an interactive ...
... 20 N y comed tod a y announced t h e su b mission of a N e ... n d Drug Administr a tion ( F DA) for ... oral treatme n t for patie n t s ... i ssion is ba s e d on enc ou raging result s fro m ...
... , , ... DIEGO, July 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today ... its investigational drug for the treatment of obesity, met their co-primary endpoints. ... O besity R esearch, or COR, program of more ...
... , , ... -- Allscripts (Nasdaq: MDRX ) announced today ... Human Resources. Ms. Adams brings to the position more than 20 ... high tech industry, most recently as Vice President of Human Resources ...
Cached Medicine News:Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 2Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 3Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Silas Home Care Selects Cardiocom Telehealth Technology 2Health News:Nycomed Announces FDA Filing for Daxas(R) in COPD 2Health News:Nycomed Announces FDA Filing for Daxas(R) in COPD 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 2Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 3Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 4
3 mm disposable bevel blades. Malleable shafts. Blades packaged 6 per package....
Straight 8 mm downcutting Royce blade. Can be placed in closed handle for protection. Rigid handle when folded and locked. Straight 8 mm downcutting blades. Handle length folded 109 mm, 4.3 inches....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: